Back4D Molecular Therapeutics Overview
4D Molecular Therapeutics Inc

4D Molecular Therapeutics Target Price

See 4D Molecular Therapeutics's analyst price targets ($33) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$14.7

Average Target Price

$32.50121.1% upside

2 analysts in the last 4 months

High: $33 | Low: $32

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-13Goldman Sachs$32117.7% upsideOpen
2026-05-08Goldman Sachs$33124.5% upsideOpen
2025-11-11BarclaysGena Wang$33124.5% upsideOpen
2025-10-31Leerink PartnersMani Foroohar$1715.6% upsideOpen
2025-10-21RBC CapitalLisa Walter$2676.9% upsideOpen
2025-01-11Morgan StanleyJudah Frommer$659.2% downsideOpen
2024-09-19BMO CapitalKostas Biliouris$40172.1% upsideOpen
2024-09-19Loop Capital MarketsGeulah Livshits$39165.3% upsideOpen
2024-09-19H.C. WainwrightMatthew Caufield$36144.9% upsideOpen
2024-04-15RBC CapitalLisa Walter$40172.1% upsideOpen
2024-04-15BarclaysGena Wang$45206.1% upsideOpen
2024-04-01JefferiesNalin Tejavibulya$58294.6% upsideOpen
2024-03-28BMO CapitalKostas Biliouris$63328.6% upsideOpen
2024-02-06BMO CapitalKostas Biliouris$70376.2% upsideOpen
2023-07-05Chardan CapitalGeulah Livshits$30104.1% upsideOpen
2022-11-18H.C. Wainwright$36144.9% upsideOpen
2022-04-05Evercore ISIJosh Schimmer$40172.1% upsideOpen

4D Molecular Therapeutics (FDMT) FAQ

4D Molecular Therapeutics's target price stands at $33. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $33 for FDMT implies 121.1% upside versus today's price ($14.7). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how 4D Molecular Therapeutics's target price evolved across reporting periods, while the comparison chart places FDMT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. 4D Molecular Therapeutics's reading of $33 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.